Image Credit: Scientific Frontline / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Triciribine and Adenosine Kinase in Acute Lymphoblastic Leukemia
The Core Concept: Adenosine kinase (ADK) is an enzyme essential for activating the therapeutic compound triciribine in patients with acute lymphoblastic leukemia (ALL). Recent multi-omics research indicates that higher cellular levels of ADK correlate with a stronger inhibitory response against leukemia cells, presenting a critical biomarker for targeted cancer treatments.
Key Distinction/Mechanism: Unlike many conventional treatments that operate broadly, triciribine must be intracellularly converted into its active form by ADK. Once activated, the compound disrupts the synthesis of essential nucleic acid building blocks (DNA and RNA), thereby halting the growth and division of leukemia cells.
Major Frameworks/Components:
- Target Compound: Triciribine, an antimetabolite drug previously hindered by variable clinical efficacy.
- Enzymatic Catalyst: Adenosine kinase (ADK), the protein responsible for metabolizing triciribine into its active, cancer-inhibiting state.
- Multi-Omics Profiling: The robust analytical approach used to map large networks of cellular proteins, revealing that triciribine disrupts the production of RNA and DNA building blocks in ALL cells.
Branch of Science: Oncology, Hematology, Molecular Biology, and Precision Medicine.
Future Application: ADK screening could be integrated into standard diagnostic protocols for acute lymphoblastic leukemia to identify specific patient subpopulations most likely to respond favorably to triciribine, thereby rescuing an otherwise inconsistent therapy for highly targeted clinical use.
Why It Matters: By predicting patient responses prior to treatment, this biomarker-guided approach minimizes unnecessary exposure to ineffective therapies and paves the way for highly individualized leukemia management. It highlights how targeted profiling can unlock the therapeutic potential of previously limited clinical compounds.
In a comprehensive study of acute lymphoblastic leukemia, researchers at Karolinska Institutet have shown that the enzyme ADK plays an important role in determining how leukemia cells respond to triciribine. Published in npj Precision Oncology, the study also provides new insights into how the compound works and identifies ADK as a potential biomarker for predicting its effects on leukemia cells.
Acute lymphoblastic leukemia (ALL) is a blood cancer that can affect people of all ages. Triciribine is a compound that has previously been investigated as a cancer treatment, but its mechanism of action in ALL cells has not been fully understood. The researchers therefore set out to investigate how triciribine acts in leukemia cells and why some cells are more susceptible to its effects than others.
To better understand how triciribine works, the researchers used several methods to study a large number of proteins in leukemia cells. This allowed them to map the cellular processes affected by the compound. Their findings suggest that triciribine disrupts several processes that leukemia cells need to grow and divide, including the production of building blocks for DNA and RNA.
One important factor was the enzyme ADK, which is required to convert triciribine into its active form inside the cell. The researchers found that triciribine had a greater effect on laboratory-grown leukemia cells with higher levels of ADK. A similar pattern was observed in ten patient samples containing leukemia cells exposed to triciribine outside the body.
“We found that ADK levels were associated with the effect of triciribine on leukemia cells. This makes ADK an interesting candidate as a potential biomarker,” says Xuekang Qi, researcher at the Department of Oncology-Pathology and first author of the study.
Previously Tested in Clinical Trials
Triciribine has previously been tested in clinical trials involving patients with blood cancers, but treatment responses have been limited. The new study is based on experiments using laboratory-grown leukemia cells and patient-derived leukemia cells studied outside the body. It therefore remains to be established whether ADK can also predict treatment response in patients.
“If ADK proves able to predict treatment response, it could improve our ability to identify patients who may benefit from triciribine. This is particularly relevant for a compound that has produced limited treatment responses in previous clinical trials,” says Rozbeh Jafari, researcher at the same department and senior author of the study.
Funding: The research was funded by, among others, the Swedish Childhood Cancer Fund, the Swedish Cancer Society, the Swedish Research Council, the Cancer Research Funds of Radiumhemmet, and Karolinska Institutet’s research foundations.
Disclosure: The researchers report no conflicts of interest.
Published in journal: npj Precision Oncology
Authors: Xuekang Qi, Georgios Mermelekas, Ondrej Hodek, Luay Aswad, Quentin Glaziou, Isabelle Rose Leo, Nona Struyf, Femke M. Hormann, Ioannis Siavelis, Henri Colyn Bwanika, Owen F. J. Hovey, Martin Haraldsson, Sean G. Rudd, Annika I. Johansson, Tom Erkers, Katja Pokrovskaja Tamm, Janne Lehtiö, and Rozbeh Jafari
Source/Credit: Karolinska Institutet
Edited by: Scientific Frontline
Reference Number: ongy101926_01
